The clinical effectiveness of clarithromycin versus endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps (MACRO): a pragmatic, multicentre, three-arm, randomised, placebo-controlled phase 4 trial

医学 慢性鼻-鼻窦炎 安慰剂 鼻息肉 克拉霉素 外科 鼻窦炎 临床试验 功能性内窥镜鼻窦手术 内科学 替代医学 幽门螺杆菌 病理
作者
Carl Martin Philpott,David John Beard,Elnaz Saeedi,Jonathan Alistair Cook,Stephen Jones,Caroline Sarah Clarke,Lucinda Teoh,Mike D. Thomas,Paul S Little,Jane Louise Vennik,Valerie Joan Lund,Anne GM Schilder,Fei Long,Stephen R. Durham,James Boardman,Claire L Hopkins,Shazada Ahmed,Robert Almeyda,Rajiv Bhalla,Helen Blackshaw
出处
期刊:The Lancet [Elsevier BV]
卷期号:406 (10506): 926-939 被引量:22
标识
DOI:10.1016/s0140-6736(25)01248-6
摘要

BACKGROUND: A paucity of evidence regarding use of endoscopic sinus surgery and antibiotics in managing chronic rhinosinusitis has contributed to a five-times variation in endoscopic sinus surgery rates, as well as variation in the use of antibiotics. The main aim of the present trial was to compare the clinical effectiveness of endoscopic sinus surgery or 3 months of clarithromycin treatment alongside intranasal medication in adults with chronic rhinosinusitis with or without nasal polyps. METHODS: In this pragmatic, three-arm, randomised, placebo-controlled phase 4 trial, participants were recruited from 20 secondary and tertiary care sites in the UK. Adults (aged ≥18 years) with chronic rhinosinusitis remaining symptomatic following appropriate medical therapy (intranasal corticosteroids, saline nasal irrigations, and a short course of antibiotics) were randomly assigned (1:1:1) to receive endoscopic sinus surgery (within 6 weeks of randomisation if waiting lists allowed) plus intranasal medication, clarithromycin (250 mg twice a day for 2 weeks then 250 mg once a day for 10 weeks) plus intranasal medication, or placebo plus intranasal medication. Intranasal medication comprised intranasal corticosteroids and saline irrigations. Participants were allocated with an automated, web-based secure randomisation system in permuted blocks of varying size (block sizes of three and six), stratified by the presence of polyps and trial site. Participants and site teams were masked to the clarithromycin and placebo allocations, including for outcome assessment. The primary outcome measure was the total score on the 22-item Sino-Nasal Outcome Test (SNOT-22) quality-of-life questionnaire at 6 months after randomisation, with analysis by intention to treat (ITT; available-case basis). Adverse reactions were assessed in the safety population (clarithromycin and placebo), and serious adverse events in the ITT population (all groups). The trial was registered on the ISRCTN registry, ISRCTN36962030, and EudraCT, 2018-001100-11, and is complete, with optional long-term follow-up ongoing. FINDINGS: Between Nov 1, 2018, and Oct 13, 2023, 514 participants (181 [35%] female and 333 [65%] male), with chronic rhinosinusitis with nasal polyps (n=410) or chronic rhinosinusitis without nasal polyps (n=104), were recruited and randomly assigned to receive endoscopic sinus surgery (n=171), clarithromycin (n=172), or placebo (n=171), all with intranasal medication. SNOT-22 scores at 6 months after randomisation were significantly lower (at the 98·33% confidence level after Bonferroni adjustment) in the endoscopic sinus surgery group than in the clarithromycin group (adjusted mean difference -18·13 [98·33% CI -24·26 to -11·99], p<0·0001) and placebo group (-20·44 [-26·42 to -14·46], p<0·0001). 6-month SNOT-22 scores did not differ significantly between participants randomly assigned to clarithromycin versus placebo (-3·11 [-8·56 to 2·33], p=0·17). Ten serious adverse events occurred in nine participants (two events in two [1%] of 172 participants allocated to clarithromycin, three events in three [2%] of 171 allocated to placebo, and five events in four [2%] of 171 allocated to endoscopic sinus surgery), none of which were fatal. INTERPRETATION: The MACRO trial shows that endoscopic sinus surgery has clinical effectiveness in patients with chronic rhinosinusitis, providing significantly improved disease-specific quality of life at 6 months. Conversely, the trial findings do not support routine long-term use of low-dose clarithromycin. Endoscopic sinus surgery should be recommended if intranasal medication alone is unable to achieve symptom control. FUNDING: National Institute for Health and Care Research Programme Grants for Applied Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风吹麦浪的应助被徐自谦采纳,获得10
刚刚
changlanya发布了新的文献求助10
刚刚
浅浅依云完成签到,获得积分10
刚刚
小艾同学发布了新的文献求助30
1秒前
薛妖怪发布了新的文献求助10
1秒前
丑角苏发布了新的文献求助10
2秒前
李健的应助被蛋包洋芋采纳,获得10
2秒前
3秒前
张啦啦完成签到 ,获得积分10
4秒前
奥黛丽赫本完成签到,获得积分10
5秒前
丸子完成签到,获得积分20
5秒前
SUNny发布了新的文献求助10
5秒前
6秒前
英姑的应助被HE采纳,获得10
6秒前
深沉坤完成签到 ,获得积分10
6秒前
郭佳雨完成签到 ,获得积分10
7秒前
Dandelion完成签到,获得积分10
7秒前
含糊的云朵完成签到 ,获得积分10
7秒前
9秒前
loser完成签到,获得积分10
10秒前
Ethan发布了新的文献求助10
12秒前
123关闭了123的文献求助
12秒前
Timber完成签到,获得积分10
12秒前
12秒前
13秒前
13秒前
清爽的元灵完成签到,获得积分10
13秒前
linp完成签到,获得积分10
13秒前
14秒前
Flaubert完成签到,获得积分10
14秒前
你很棒完成签到,获得积分10
15秒前
孩他妈完成签到,获得积分10
16秒前
17秒前
17秒前
阿狸完成签到 ,获得积分10
18秒前
鱼七发布了新的文献求助10
18秒前
linp发布了新的文献求助10
18秒前
万能图书馆的应助被朴实凌旋采纳,获得10
18秒前
乐乐的应助被IDENTIFY采纳,获得10
19秒前
研友_VZG7GZ的应助被fqw采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527